clinical trial · NCT02993406
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
Cardiovascular DiseasesStatin Adverse ReactionBempedoic acid 180 mg tabletMatching placebo tablet
brief summary
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
started
Dec 22, 2016
primary completion
Nov 7, 2022
completion
Nov 7, 2022
last updated
Jan 3, 2024
official title
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol